Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) was downgraded by investment analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a note issued to investors on Thursday, Zacks reports.
A number of other research analysts have also recently weighed in on PTGX. Wedbush reissued an "outperform" rating on shares of Protagonist Therapeutics in a research note on Monday, November 9th. Truist Financial lifted their price objective on Protagonist Therapeutics from $145.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. The Goldman Sachs Group raised Protagonist Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $110.00 to $186.00 in a research note on Monday, August 10th. UBS Group reiterated a "buy" rating on shares of Protagonist Therapeutics in a report on Tuesday, November 3rd. Finally, Wolfe Research reiterated an "outperform" rating on shares of Protagonist Therapeutics in a research report on Monday, August 31st. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $166.67.
Check Out Our Latest Analysis on Protagonist Therapeutics
Protagonist Therapeutics Stock Down 2.1%
NASDAQ:PTGX opened at $121.40 on Thursday. Protagonist Therapeutics has a 52-week low of $77.00 and a 52-week high of $160.81. The stock has a fifty day simple moving average of $138.14 and a 200-day simple moving average of $120.16. The company has a market capitalization of $7.92 billion, a PE ratio of 25.72 and a beta of 1.21.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.57. The firm had revenue of $274.41 million for the quarter, compared to analysts' expectations of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. As a group, equities analysts anticipate that Protagonist Therapeutics will post 5.52 earnings per share for the current year.
Insiders Place Their Bets
In other news, CFO Asif Ali sold 58,629 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the transaction, the chief financial officer directly owned 59,003 shares in the company, valued at $8,365,445.34. This represents a 49.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 7,278 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the transaction, the chief executive officer owned 522,968 shares in the company, valued at approximately $75,359,688.80. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 186,347 shares of company stock valued at $26,891,786. Insiders own 5.19% of the company's stock.
Hedge Funds Weigh In On Protagonist Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at $1,263,535,000. Johnson & Johnson acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter worth $300,220,852. Jupiter Topco LLC acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter worth $261,039,000. Bank of America Corp DE acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter worth $162,357,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter worth $117,783,000. Institutional investors and hedge funds own 98.63% of the company's stock.
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company's programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.